Postural orthostatic tachycardia syndrome is an autonomic nervous system disorder having symptoms such as, light-headedness, sweating, anxiety, fatigue, tremors, palpitation and orthostatic intolerance. Postural orthostatic tachycardia syndrome is a category of disease rather than a single illness. In this condition patient’s heart rate increase by 30 beats per minute in standing position reaching to more than 120 beats per minute as compare to resting or lying position. Patients with postural orthostatic tachycardia syndrome have change in blood pressure which can fluctuate in either direction means hypertension or hypotension. Postural orthostatic tachycardia syndrome can be classified in primary forms and secondary forms. This condition can limit the patient’s life and obstruct him performing daily activities, e.g. feeding, household work, walking etc. Usually, this condition affect age group of 12-50 years with females being affected five times more than the males. Postural orthostatic tachycardia syndrome can be treated using both pharmacological and non-pharmacological measure. Pharmacological measures are used when non-pharmacological measures are unable to manage postural orthostatic tachycardia syndrome.
Postural Orthostatic Tachycardia Syndrome Treatment Market: Drivers and Restraints
Increasing awareness among physicians regarding the postural orthostatic tachycardia syndrome is expected to growth of treatment market. Due to mystifying nature of postural orthostatic tachycardia syndrome various international bodies such as, MyHeart are conducting research and surveys to understand the nature of syndrome for proper diagnosis and treatment. Increasing focus of these international bodies to study this condition is expected to fuel the growth of postural orthostatic tachycardia syndrome treatment market. Unavailability of specific treatment option can serve as restraint. Misdiagnosis of postural orthostatic tachycardia syndrome as anxiety, panic attack and depression is also a hindrance in the growth of market.
Postural Orthostatic Tachycardia Syndrome Treatment Market: Segmentation
The global postural orthostatic tachycardia syndrome treatment market can be segmented by End User and Region.
On the basis of end user the global postural orthostatic tachycardia syndrome treatment market can be segmented as:
Hospitals, Clinics, Ambulatory Surgical Centers, Research Institutes
Postural Orthostatic Tachycardia Syndrome Treatment Market: Overview
Postural orthostatic tachycardia syndrome treatment market is expected to show significant growth over the forecast period owning to factors such as, increasing awareness and diagnosis. Unavailability of the specific treatment is a hindrance for the growth of postural orthostatic tachycardia syndrome but few drugs are under clinical trials which are expected to get marketing approval over the forecast period and fuel the growth of postural orthostatic tachycardia syndrome treatment market. Availability off-label treatment option is also expected to boost the growth. Various research institutes and medical institutions are developing specific drugs which are expected to fuels the growth of postural orthostatic tachycardia syndrome market.
Postural Orthostatic Tachycardia Syndrome Treatment Market: Region Wise Outlook
Geographically, the global orthostatic tachycardia syndrome treatment market can be segmented into regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to be biggest and fastest growing postural orthostatic tachycardia syndrome treatment market owning to increasing clinical trials in the region, increasing awareness and better healthcare infrastructures. Followed by which is Europe. Asia Pacific is also expected to show a slight growth in postural orthostatic tachycardia treatment market due to higher prevalence of cardiac disease in this region. Increasing awareness and diagnosis is also expected to drive the growth in this region.
Postural Orthostatic Tachycardia Syndrome Treatment Market: Key Players
Some of the market participants in the global postural orthostatic syndrome treatment market are Pfizer, Inc., Novartis AG, AstraZeneca, Merck & Co.,Inc., Sanofi S.A., Daiichi Sankyo Company, Limited and Bayer AG. Companies in collaboration with research institutes are investing in research and development for specific drug development to treat postural orthostatic tachycardia syndrome.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/15700
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15700